Cleveland Clinic:把脉2018十大医疗科技创新,PCSK9抑制剂入选

2017-12-04 岱西 中国循环杂志

每年的医疗创新峰会上,克利夫兰医学中心(Cleveland Clinic)的专家们都会把脉未来。在2018年,哪些创新更有前景?


每年的医疗创新峰会上,克利夫兰医学中心(Cleveland Clinic)的专家们都会把脉未来。在2018年,哪些创新更有前景?
 
1、“人造胰腺”控制血糖
 
将连续血糖监测和胰岛素泵紧密相接,更显“人性化”,无需要求患者根据血糖监测来计算胰岛素用量,很方便1型糖尿病患者管理自己的血糖。
 
2、神经调节治疗阻塞性睡眠呼吸暂停
 
一些公司开发了一种类似于起搏器的植入设备,通过远程遥控或可穿戴芯片控制其中植入的呼吸传感器和刺激导线,使得在睡眠时刺激相关神经开放气道肌肉,并且让吸气和舌头活动同步。
 
3、基因疗法有望终结遗传性视网膜疾病
 
预计在2018年,FDA将会通过一项针对遗传性视网膜疾病的新型基因疗法。这种治疗方法通过病毒载体向靶细胞运送新基因,以改善Leber先天性黑朦和视网膜色素变性患者的视力。
 
4、PCSK9抑制剂使低密度胆固醇史无前例地降低
 
在高血脂面前,他汀类药物有时会力不从心,并不能完全满足临床需求。不过近年来出现的PCSK9 抑制剂让人眼前一亮。
 
研究显示,他汀+PCSK9 抑制剂可使LDL水平降至更低,患者心脏猝死、心梗或卒中的风险会降低20%。

5、远程医疗将蓬勃发展
 
随着移动科技的发展和患者需求的增加,很多医院已经为2018年远程医疗的普及做了很多工作。据报道,90%的医疗机构运营者已经或正在建立远程医疗服务平台,预计2018年使用远程医疗的患者将达到700万人,比2013年增长了19倍。
 
此外,各种穿戴式远程监测设备也在助力远程医疗,这使得医生更方便隔空监测患者病情、管理疾病。预计2018年,将有1900多万患者将使用这些远程监测设备。
 
6、开发、运输、储存和接种疫苗的平台将全方位升级
 
2018年,原有疫苗平台将全面升级,以期加速研发、更好储存和运输以及接种等,预防当前和未来的流行病。
 
比如,有公司正在完善冷冻干燥疫苗,以便运往更偏远的地方。还有公司应用烟草植物、昆虫和纳米颗粒以更快开发流感疫苗。
 
疫苗的使用也会让人耳目一新,除了传统的皮下注射外,口服、粘膜输送、疫苗芯片等均在研发中。比如2018年,流感疫苗贴片将会问世。
 
7、多种靶向疗法治疗乳腺癌
 
2018年靶向治疗将广泛地用于治疗乳腺癌。
 
多种新型靶向疗法,比如针对BRCA1和BRCA2特异突变的PARP抑制剂,和全新的针对ER-阳性/HER2-阴性的CDK4/6抑制剂,都在临床试验中表现不俗。此外,新型HER-2靶向药物对部分HER-2阳性患者也显示有益。
 
8、强化术后恢复:缩短住院,减少阿片类药物应用
 
最新研究显示,强化的术后康复方案(ERAS)可减少并发症,并促进康复。
 
ERAS包括术前进食、用其他药物替代阿片类药物和鼓励下床走动等。研究表明,这些方法可减少血栓形成、恶心、感染、肌肉萎缩,并缩短住院时间。此外,患者还接受术后营养治疗,以及限制麻醉药的使用的多种镇痛方式。
 
9、中央监测住院患者:有效克服“警报疲乏”,增加心脏骤停患者生存率
 
长期以来,“警报疲乏”(alarm fatigue)令人挠头:忙碌的医护人员对叫个不停的心脏监护仪不再敏感,重要的警报在噪音中被淹没。
 
研究发现,高达44%的住院患者的心脏骤停没能及时发现。而根据美国心脏协会的数据,发生心脏骤停的住院患者中,只有不到四分之一能存活下来。
 
而中央监测可以很好解决这一切。所谓的中央监测,就是非现场工作人员使用先进设备,如感应器和高清摄像头来监测患者的血压、心率、呼吸、脉搏血氧仪等。同时将各种数据汇总并过滤掉次要信息,只在必要时给在岗医护发出警报,启动适时现场干预。
 
有研究发现,使用中央监测预警后,心跳呼吸骤停患者的生存率达到93%。
 
10、头皮冷却术减少化疗脱发
 
对于化疗的女性癌症患者而言,脱发不仅是影响美观,还对心理有一定打击。
 
有研究发现,化疗前、中、后期降低头皮温度几度,可有效保留头发。目前已经在接受化疗的乳腺癌早期患者中较为见效。而头皮冷却系统已经于2017年5月经FDA批准。
 
原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2018-09-29 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2018-03-11 FukaiBao
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2017-12-29 Tamikia
  6. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2017-12-06 mnda
  9. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1786853, encodeId=d2061e868539d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Dec 17 10:31:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851587, encodeId=5051185158ec5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 29 13:31:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777256, encodeId=05351e77256af, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Mar 11 01:31:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758572, encodeId=d3dd1e5857277, content=<a href='/topic/show?id=9aab549134b' target=_blank style='color:#2F92EE;'>#把脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54913, encryptionId=9aab549134b, topicName=把脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1dc37340209, createdName=ms2186806800017884, createdTime=Fri Jan 19 14:31:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685600, encodeId=47e816856002a, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 29 22:31:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285486, encodeId=c35b1285486df, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481662, encodeId=4c40148166257, content=<a href='/topic/show?id=2f2b35e0581' target=_blank style='color:#2F92EE;'>#十大医疗科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35705, encryptionId=2f2b35e0581, topicName=十大医疗科技创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0fff7811434, createdName=12498b37m74暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536844, encodeId=fb4e1536844f7, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617637, encodeId=ff32161e63743, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Wed Dec 06 11:31:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266801, encodeId=146c26680110, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Mon Dec 04 21:09:42 CST 2017, time=2017-12-04, status=1, ipAttribution=)]
    2017-12-04 thlabcde

    好资料学习了!

    0

相关资讯

2018年国家自然基金申请的时间节点

2017年国自然申请已经成为历史,接下来就是准备2018年的申请了!

2018年NSFC申请书的摘要如何写?

2018年NSFC摘要不会写?怎么办?哪儿可以查到已经获得资助的NSFC项目?且看我们的介绍!

高血压130/80mmHg,对2018年NSFC申请的影响

今天,刷爆朋友圈的,是2017年美国心脏协会(AHA)科学年会上,重新定义的高血压:≥130/80mmHg。那么,从科研角度,尤其是2018年NSFC申请角度来看,又有什么影响呢?

对医生来说,2018年国自然(NSFC)距离提交只剩1个月了

今天已经是2017年11月16日,医生朋友们,到2018年3月初,2018年NSFC只剩1个月就提交了!为何说是只剩1个月呢?请大家仔细看看: